lorcaserin

[Anonymous]

Arena Pharmaceuticals is cutting 25% of its staff, or 66 employees, by the end of March. The move isn’t unexpected. Last fall, FDA gave the San Diego-based biotech a thumbs down for its obesity drug lorcaserin based on concerns that it had caused tumors in rats. Now, FDA is asking for a slew of new data, meaning Arena will be unlikely to refile its application for approval until 2012, analysts say. See here and here for more on its lorcaserin trials and tribulations.

 

[Anonymous]

Arena Pharmaceuticals is cutting 25% of its staff, or 66 employees, by the end of March. The move isn’t unexpected. Last fall, FDA gave the San Diego-based biotech a thumbs down for its obesity drug lorcaserin based on concerns that it had caused tumors in rats. Now, FDA is asking for a slew of new data, meaning Arena will be unlikely to refile its application for approval until 2012, analysts say. See here and here for more on its lorcaserin trials and tribulations.

Any you wonder why other pharma companies took a pass on this drug. Oh well, another LC blunder. Someone check LC's skin because it must be made of teflon. The guy makes major blunder after major blunder yet he keeps his job.

 

[Anonymous]

"Yeah, guys," LC says, " but if this drug's a go it would have been worth the gamble!" Name that drug... Zonegran, lorcaserin, colazal...